Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds

Amarin Corporation Plc ((AMRN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Amarin’s latest earnings call painted a cautiously upbeat picture for investors, with management stressing sharp cost cuts, shrinking operating losses, positive cash generation, and a well‑funded balance sheet. These operational wins were offset by a double‑digit revenue decline, ongoing U.S. pricing pressure, and choppy international sales as the company shifts to a partner‑driven model.

Deep Cost Cuts Drive Leaner Operating Model

Total operating expenses in Q4 dropped 31% year over year, or $13.5 million, reflecting aggressive restructuring across the business. Excluding restructuring charges, OpEx was down 41%, while SG&A fell 46% and shrank to 41% of net sales versus 59% a year earlier, signaling a structurally leaner commercial footprint.

Cash Flow Turns Positive and Balance Sheet Stays Strong

Amarin generated $7.0 million of cash from operations in 2025, a key milestone for a company still posting an accounting loss. It closed the year with $303 million in cash and investments, no debt, and $455 million in working capital, giving it ample runway to fund commercialization and withstand revenue volatility.

Recordati Partnership Unlocks Immediate and Future Value

The long‑term license and supply deal with Recordati, covering 59 countries with a focus on Europe, closed in mid‑2025 and delivered an upfront $25 million payment. The arrangement also includes up to $150 million in milestones tied to commercial performance, enabling Recordati‑led European launches while Amarin benefits from scale without carrying full local costs.

Operating Loss Narrows Sharply

Underlying operating performance improved markedly, with Q4 operating loss reduced to $2.3 million from $16.0 million in the prior‑year quarter, excluding restructuring. This demonstrates that cost actions and shifting to a partnered model are beginning to translate into better margins, even as top‑line pressure persists.

Vascepa Maintains U.S. Leadership and Scientific Edge

Despite heavy generic competition, Vascepa remains the leading icosapent ethyl product in the U.S. five years after the first generic launch, supported by roughly 30 million prescriptions since 2013. Management underscored the robust data set, including the REDUCE‑IT trial’s 25% reduction in major cardiovascular events and a steady stream of new publications and scientific presentations.

International Expansion Gathers Momentum Through Partners

Outside the U.S., Amarin and its partners are making tangible regulatory and launch progress, notably approvals in South Korea and Singapore with launches in preparation. Recordati has advanced commercialization in Italy and secured pricing and reimbursement in Austria and Slovenia, while reviews in Thailand and the Philippines and new filings in Vietnam and Malaysia are slated for 2026.

Restructuring Savings Tracking to Plan

By year‑end 2025, Amarin had realized about half of its targeted $70 million in annual operating expense savings from its global restructuring. Management affirmed that full run‑rate savings should be in place by June 30, 2026, suggesting further margin tailwind once the last restructuring steps and related charges are completed.

Revenue Declines Highlight Top‑Line Pressure

Q4 2025 net revenue fell to $49.2 million from $62.3 million a year earlier, a roughly 21% drop that underlines the company’s growth challenge. The decline came even as costs fell sharply, highlighting that Amarin’s path to sustainable profitability depends on stabilizing or re‑accelerating revenue, particularly in the U.S. and new markets.

Rest‑of‑World Sales Hit by Prior Stocking Comparisons

Rest‑of‑world revenue plunged to $3.1 million in Q4 from $11.9 million in the prior‑year quarter, a roughly 74% decline. Management attributed most of the fall to $7.8 million of stocking orders in 2024 that did not repeat, underscoring how one‑time orders can distort year‑over‑year comparisons as partners build or normalize inventory.

U.S. Pricing Actions and Expected Q1 Volume Headwinds

In the U.S., sales dropped 7% in Q4, driven mainly by a lower net selling price tied to proactive pricing decisions in a generic‑heavy market. Management warned that most of the full‑year 2026 U.S. volume decline is likely to be front‑loaded into Q1 due to seasonal payer dynamics, with continued pricing pressure expected as generics compete aggressively.

Partnered Model Introduces Revenue Volatility

As Amarin shifts to a partnered international model, quarterly revenue becomes more sensitive to launch timing and supply shipments rather than steady in‑market sales. In Q4, Europe product revenue totaled $2.3 million, including $0.9 million from supply shipments, and the company expects revenue from these regions to skew increasingly toward supply‑based recognition.

Restructuring Charges Depress Near‑Term Results

The company booked $36.2 million in restructuring costs for 2025, with $4.1 million in Q4, reflecting the financial hit from its broad cost‑cutting program. Management expects the final restructuring charges to occur in early 2026, suggesting that while the cash and expense burden is near term, the savings benefit should persist.

Competitive and Managed‑Care Risks Remain in Focus

The U.S. market remains highly competitive, with multiple generic entrants and shifting payer decisions that can alter coverage and exclusivity. Amarin noted it lost a major pharmacy benefit manager in mid‑2024 and regained it in 2025, illustrating the importance and risk of managed‑care relationships for maintaining pricing power and prescription volume.

Guidance Underscores Cost Discipline and Cash Generation

Looking ahead, Amarin expects to capture the full $70 million in annualized restructuring savings by mid‑2026, after already realizing roughly half by year‑end 2025. Management reiterated an outlook for positive full‑year 2026 cash flow, supported by the strong $303 million cash balance, no debt, and incremental upside potential from Recordati milestones, while cautioning that partnered revenue and U.S. volumes will remain lumpy.

Amarin’s earnings call framed a company in transition, trading near‑term revenue softness and restructuring charges for a leaner, cash‑generative model anchored by partnerships. For investors, the story now hinges on execution: preserving U.S. franchise value, converting international approvals into durable sales, and proving that the new, lower‑cost structure can translate operational progress into sustainable profitability.